Autek China Inc
SZSE:300595
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
13.27
24.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Autek China Inc
Autek China Inc
Total Receivables
Autek China Inc
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Autek China Inc
SZSE:300595
|
Total Receivables
¥353.1m
|
CAGR 3-Years
17%
|
CAGR 5-Years
24%
|
CAGR 10-Years
N/A
|
|
|
Shandong Weigao Group Medical Polymer Co Ltd
HKEX:1066
|
Total Receivables
¥8B
|
CAGR 3-Years
9%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Eyebright Medical Technology Beijing Co Ltd
SSE:688050
|
Total Receivables
¥244.1m
|
CAGR 3-Years
40%
|
CAGR 5-Years
37%
|
CAGR 10-Years
N/A
|
|
|
Autobio Diagnostics Co Ltd
SSE:603658
|
Total Receivables
¥1.3B
|
CAGR 3-Years
9%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Winner Medical Co Ltd
SZSE:300888
|
Total Receivables
¥1.1B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
|
Total Receivables
¥712.4m
|
CAGR 3-Years
48%
|
CAGR 5-Years
27%
|
CAGR 10-Years
N/A
|
|
Autek China Inc
Glance View
Autek China Inc. stands as an emblematic figure in the dynamic landscape of medical devices and biotechnology in China. Rooted in its mission to innovate within the realms of diagnostic imaging and therapeutic ultrasound equipment, the company has maneuvered through this niche market by leveraging both cutting-edge technology and strategic partnerships. Autek's portfolio includes a range of high-quality ultrasound machines and imaging solutions that cater to the rapidly evolving needs of hospitals and clinics. By capitalizing on the growing demand for advanced healthcare services in China, Autek has tailored its product offerings to resonate with local market needs while maintaining competitive pricing strategies. This keen understanding of market dynamics allows Autek to maintain a robust sales pipeline and forge sturdy relationships within the medical community, driving its revenue growth engine. The company's operational blueprint hinges on an impressive blend of research-driven innovation and effective distribution networks. Autek continually invests in research and development, aspiring to push technological boundaries and uphold its reputation as a pioneer in the medical imaging sector. This investment lays the groundwork for creating state-of-the-art products that are not only technologically advanced but also user-friendly for medical professionals. Autek's adeptness at navigating regulatory landscapes ensures smooth market entry and expansion for its offerings. Furthermore, its strategic alliances with healthcare providers and government entities enhance its distribution network, ensuring that its products reach a wide spectrum of healthcare institutions across China. Autek makes its money by selling its technologically advanced and reliable devices, as well as providing ongoing support and maintenance services, forming the backbone of its revenue model and securing its position in the competitive arena.
See Also
What is Autek China Inc's Total Receivables?
Total Receivables
353.1m
CNY
Based on the financial report for Sep 30, 2024, Autek China Inc's Total Receivables amounts to 353.1m CNY.
What is Autek China Inc's Total Receivables growth rate?
Total Receivables CAGR 5Y
24%
Over the last year, the Total Receivables growth was 6%. The average annual Total Receivables growth rates for Autek China Inc have been 17% over the past three years , 24% over the past five years .
You don't have any saved screeners yet